nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Vomiting—Vinblastine—testicular cancer	0.00195	0.00195	CcSEcCtD
Regadenoson—Renal impairment—Doxorubicin—testicular cancer	0.00194	0.00194	CcSEcCtD
Regadenoson—Malaise—Etoposide—testicular cancer	0.00194	0.00194	CcSEcCtD
Regadenoson—Headache—Vinblastine—testicular cancer	0.00193	0.00193	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00192	0.00192	CcSEcCtD
Regadenoson—Abdominal pain—Dactinomycin—testicular cancer	0.00191	0.00191	CcSEcCtD
Regadenoson—Anaphylactic shock—Cisplatin—testicular cancer	0.00191	0.00191	CcSEcCtD
Regadenoson—Hypersensitivity—Bleomycin—testicular cancer	0.00191	0.00191	CcSEcCtD
Regadenoson—Cardiac arrest—Epirubicin—testicular cancer	0.0019	0.0019	CcSEcCtD
Regadenoson—Pain—Ifosfamide—testicular cancer	0.0019	0.0019	CcSEcCtD
Regadenoson—Loss of consciousness—Etoposide—testicular cancer	0.00189	0.00189	CcSEcCtD
Regadenoson—Cerebrovascular accident—Doxorubicin—testicular cancer	0.00189	0.00189	CcSEcCtD
Regadenoson—Nervous system disorder—Cisplatin—testicular cancer	0.00188	0.00188	CcSEcCtD
Regadenoson—Cough—Etoposide—testicular cancer	0.00187	0.00187	CcSEcCtD
Regadenoson—Tachycardia—Cisplatin—testicular cancer	0.00187	0.00187	CcSEcCtD
Regadenoson—Asthenia—Bleomycin—testicular cancer	0.00186	0.00186	CcSEcCtD
Regadenoson—Convulsion—Etoposide—testicular cancer	0.00186	0.00186	CcSEcCtD
Regadenoson—Skin disorder—Cisplatin—testicular cancer	0.00186	0.00186	CcSEcCtD
Regadenoson—Hypertension—Etoposide—testicular cancer	0.00185	0.00185	CcSEcCtD
Regadenoson—Pain in extremity—Doxorubicin—testicular cancer	0.00185	0.00185	CcSEcCtD
Regadenoson—Hyperhidrosis—Cisplatin—testicular cancer	0.00185	0.00185	CcSEcCtD
Regadenoson—Asthma—Methotrexate—testicular cancer	0.00185	0.00185	CcSEcCtD
Regadenoson—Feeling abnormal—Ifosfamide—testicular cancer	0.00183	0.00183	CcSEcCtD
Regadenoson—Chest pain—Etoposide—testicular cancer	0.00183	0.00183	CcSEcCtD
Regadenoson—Nausea—Vinblastine—testicular cancer	0.00183	0.00183	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00182	0.00182	CcSEcCtD
Regadenoson—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00181	0.00181	CcSEcCtD
Regadenoson—Discomfort—Etoposide—testicular cancer	0.00181	0.00181	CcSEcCtD
Regadenoson—Hypotension—Cisplatin—testicular cancer	0.00179	0.00179	CcSEcCtD
Regadenoson—Hypersensitivity—Dactinomycin—testicular cancer	0.00178	0.00178	CcSEcCtD
Regadenoson—Abdominal discomfort—Methotrexate—testicular cancer	0.00177	0.00177	CcSEcCtD
Regadenoson—Urticaria—Ifosfamide—testicular cancer	0.00176	0.00176	CcSEcCtD
Regadenoson—Cardiac arrest—Doxorubicin—testicular cancer	0.00176	0.00176	CcSEcCtD
Regadenoson—Abdominal pain—Ifosfamide—testicular cancer	0.00175	0.00175	CcSEcCtD
Regadenoson—Anaphylactic shock—Etoposide—testicular cancer	0.00175	0.00175	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00174	0.00174	CcSEcCtD
Regadenoson—Abdominal distension—Epirubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Regadenoson—Asthenia—Dactinomycin—testicular cancer	0.00174	0.00174	CcSEcCtD
Regadenoson—Asthma—Epirubicin—testicular cancer	0.00173	0.00173	CcSEcCtD
Regadenoson—Paraesthesia—Cisplatin—testicular cancer	0.00172	0.00172	CcSEcCtD
Regadenoson—Tachycardia—Etoposide—testicular cancer	0.00171	0.00171	CcSEcCtD
Regadenoson—Dyspnoea—Cisplatin—testicular cancer	0.00171	0.00171	CcSEcCtD
Regadenoson—Skin disorder—Etoposide—testicular cancer	0.0017	0.0017	CcSEcCtD
Regadenoson—Hyperhidrosis—Etoposide—testicular cancer	0.00169	0.00169	CcSEcCtD
Regadenoson—Angina pectoris—Epirubicin—testicular cancer	0.00168	0.00168	CcSEcCtD
Regadenoson—Diarrhoea—Dactinomycin—testicular cancer	0.00166	0.00166	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00165	0.00165	CcSEcCtD
Regadenoson—Vomiting—Bleomycin—testicular cancer	0.00165	0.00165	CcSEcCtD
Regadenoson—Hypotension—Etoposide—testicular cancer	0.00164	0.00164	CcSEcCtD
Regadenoson—Rash—Bleomycin—testicular cancer	0.00164	0.00164	CcSEcCtD
Regadenoson—Pain—Cisplatin—testicular cancer	0.00164	0.00164	CcSEcCtD
Regadenoson—Dermatitis—Bleomycin—testicular cancer	0.00164	0.00164	CcSEcCtD
Regadenoson—Hypersensitivity—Ifosfamide—testicular cancer	0.00163	0.00163	CcSEcCtD
Regadenoson—Renal failure—Methotrexate—testicular cancer	0.00162	0.00162	CcSEcCtD
Regadenoson—Abdominal distension—Doxorubicin—testicular cancer	0.00161	0.00161	CcSEcCtD
Regadenoson—Asthma—Doxorubicin—testicular cancer	0.0016	0.0016	CcSEcCtD
Regadenoson—Asthenia—Ifosfamide—testicular cancer	0.00159	0.00159	CcSEcCtD
Regadenoson—Feeling abnormal—Cisplatin—testicular cancer	0.00158	0.00158	CcSEcCtD
Regadenoson—Paraesthesia—Etoposide—testicular cancer	0.00157	0.00157	CcSEcCtD
Regadenoson—Dyspnoea—Etoposide—testicular cancer	0.00156	0.00156	CcSEcCtD
Regadenoson—Somnolence—Etoposide—testicular cancer	0.00156	0.00156	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—testicular cancer	0.00156	0.00156	CcSEcCtD
Regadenoson—Nausea—Bleomycin—testicular cancer	0.00154	0.00154	CcSEcCtD
Regadenoson—Vomiting—Dactinomycin—testicular cancer	0.00154	0.00154	CcSEcCtD
Regadenoson—Rash—Dactinomycin—testicular cancer	0.00153	0.00153	CcSEcCtD
Regadenoson—Diarrhoea—Ifosfamide—testicular cancer	0.00152	0.00152	CcSEcCtD
Regadenoson—Renal failure—Epirubicin—testicular cancer	0.00151	0.00151	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Etoposide—testicular cancer	0.00151	0.00151	CcSEcCtD
Regadenoson—Pain—Etoposide—testicular cancer	0.0015	0.0015	CcSEcCtD
Regadenoson—Dizziness—Ifosfamide—testicular cancer	0.00147	0.00147	CcSEcCtD
Regadenoson—Feeling abnormal—Etoposide—testicular cancer	0.00144	0.00144	CcSEcCtD
Regadenoson—Nausea—Dactinomycin—testicular cancer	0.00144	0.00144	CcSEcCtD
Regadenoson—Gastrointestinal pain—Etoposide—testicular cancer	0.00143	0.00143	CcSEcCtD
Regadenoson—Vomiting—Ifosfamide—testicular cancer	0.00141	0.00141	CcSEcCtD
Regadenoson—Hypersensitivity—Cisplatin—testicular cancer	0.00141	0.00141	CcSEcCtD
Regadenoson—Bradycardia—Epirubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—testicular cancer	0.0014	0.0014	CcSEcCtD
Regadenoson—Rash—Ifosfamide—testicular cancer	0.0014	0.0014	CcSEcCtD
Regadenoson—Dermatitis—Ifosfamide—testicular cancer	0.0014	0.0014	CcSEcCtD
Regadenoson—Urticaria—Etoposide—testicular cancer	0.00139	0.00139	CcSEcCtD
Regadenoson—Abdominal pain—Etoposide—testicular cancer	0.00139	0.00139	CcSEcCtD
Regadenoson—Eye disorder—Methotrexate—testicular cancer	0.00138	0.00138	CcSEcCtD
Regadenoson—Tinnitus—Methotrexate—testicular cancer	0.00138	0.00138	CcSEcCtD
Regadenoson—Hypoaesthesia—Epirubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
Regadenoson—Asthenia—Cisplatin—testicular cancer	0.00137	0.00137	CcSEcCtD
Regadenoson—Cardiac disorder—Methotrexate—testicular cancer	0.00137	0.00137	CcSEcCtD
Regadenoson—Connective tissue disorder—Epirubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Regadenoson—Angiopathy—Methotrexate—testicular cancer	0.00134	0.00134	CcSEcCtD
Regadenoson—Immune system disorder—Methotrexate—testicular cancer	0.00133	0.00133	CcSEcCtD
Regadenoson—Mediastinal disorder—Methotrexate—testicular cancer	0.00133	0.00133	CcSEcCtD
Regadenoson—Nausea—Ifosfamide—testicular cancer	0.00132	0.00132	CcSEcCtD
Regadenoson—Diarrhoea—Cisplatin—testicular cancer	0.00131	0.00131	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—testicular cancer	0.0013	0.0013	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—testicular cancer	0.00129	0.00129	CcSEcCtD
Regadenoson—Eye disorder—Epirubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Regadenoson—Hypersensitivity—Etoposide—testicular cancer	0.00129	0.00129	CcSEcCtD
Regadenoson—Tinnitus—Epirubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Regadenoson—Erythema—Methotrexate—testicular cancer	0.00129	0.00129	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Regadenoson—Flushing—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—testicular cancer	0.00126	0.00126	CcSEcCtD
Regadenoson—Asthenia—Etoposide—testicular cancer	0.00126	0.00126	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Regadenoson—Vomiting—Cisplatin—testicular cancer	0.00122	0.00122	CcSEcCtD
Regadenoson—Vision blurred—Methotrexate—testicular cancer	0.00121	0.00121	CcSEcCtD
Regadenoson—Mental disorder—Epirubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Regadenoson—Rash—Cisplatin—testicular cancer	0.00121	0.00121	CcSEcCtD
Regadenoson—Dermatitis—Cisplatin—testicular cancer	0.0012	0.0012	CcSEcCtD
Regadenoson—Erythema—Epirubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Regadenoson—Diarrhoea—Etoposide—testicular cancer	0.0012	0.0012	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Regadenoson—Ill-defined disorder—Methotrexate—testicular cancer	0.00119	0.00119	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Regadenoson—Dysgeusia—Epirubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Regadenoson—Malaise—Methotrexate—testicular cancer	0.00116	0.00116	CcSEcCtD
Regadenoson—Dizziness—Etoposide—testicular cancer	0.00116	0.00116	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Regadenoson—Nausea—Cisplatin—testicular cancer	0.00114	0.00114	CcSEcCtD
Regadenoson—Vision blurred—Epirubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Regadenoson—Cough—Methotrexate—testicular cancer	0.00112	0.00112	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Regadenoson—Ill-defined disorder—Epirubicin—testicular cancer	0.00112	0.00112	CcSEcCtD
Regadenoson—Convulsion—Methotrexate—testicular cancer	0.00111	0.00111	CcSEcCtD
Regadenoson—Vomiting—Etoposide—testicular cancer	0.00111	0.00111	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Regadenoson—Rash—Etoposide—testicular cancer	0.0011	0.0011	CcSEcCtD
Regadenoson—Dermatitis—Etoposide—testicular cancer	0.0011	0.0011	CcSEcCtD
Regadenoson—Headache—Etoposide—testicular cancer	0.0011	0.0011	CcSEcCtD
Regadenoson—Chest pain—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Regadenoson—Arthralgia—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Regadenoson—Myalgia—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Regadenoson—Malaise—Epirubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—testicular cancer	0.00108	0.00108	CcSEcCtD
Regadenoson—Syncope—Epirubicin—testicular cancer	0.00108	0.00108	CcSEcCtD
Regadenoson—Palpitations—Epirubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Regadenoson—Loss of consciousness—Epirubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Regadenoson—Cough—Epirubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Regadenoson—Anaphylactic shock—Methotrexate—testicular cancer	0.00105	0.00105	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Regadenoson—Convulsion—Epirubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Regadenoson—Nausea—Etoposide—testicular cancer	0.00104	0.00104	CcSEcCtD
Regadenoson—Hypertension—Epirubicin—testicular cancer	0.00104	0.00104	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Regadenoson—Nervous system disorder—Methotrexate—testicular cancer	0.00103	0.00103	CcSEcCtD
Regadenoson—Myalgia—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Regadenoson—Chest pain—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—testicular cancer	0.00102	0.00102	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—testicular cancer	0.00101	0.00101	CcSEcCtD
Regadenoson—Discomfort—Epirubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—testicular cancer	0.001	0.001	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—testicular cancer	0.000999	0.000999	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—testicular cancer	0.000984	0.000984	CcSEcCtD
Regadenoson—Anaphylactic shock—Epirubicin—testicular cancer	0.000982	0.000982	CcSEcCtD
Regadenoson—Hypotension—Methotrexate—testicular cancer	0.000981	0.000981	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—testicular cancer	0.000979	0.000979	CcSEcCtD
Regadenoson—Cough—Doxorubicin—testicular cancer	0.000972	0.000972	CcSEcCtD
Regadenoson—Shock—Epirubicin—testicular cancer	0.000966	0.000966	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—testicular cancer	0.000965	0.000965	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—testicular cancer	0.000963	0.000963	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—testicular cancer	0.000961	0.000961	CcSEcCtD
Regadenoson—Tachycardia—Epirubicin—testicular cancer	0.000959	0.000959	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000956	0.000956	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—testicular cancer	0.000954	0.000954	CcSEcCtD
Regadenoson—Hyperhidrosis—Epirubicin—testicular cancer	0.000949	0.000949	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—testicular cancer	0.000949	0.000949	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—testicular cancer	0.000948	0.000948	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—testicular cancer	0.000948	0.000948	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—testicular cancer	0.000948	0.000948	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—testicular cancer	0.000945	0.000945	CcSEcCtD
Regadenoson—Paraesthesia—Methotrexate—testicular cancer	0.000942	0.000942	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000941	0.000941	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—testicular cancer	0.000937	0.000937	CcSEcCtD
Regadenoson—Dyspnoea—Methotrexate—testicular cancer	0.000936	0.000936	CcSEcCtD
Regadenoson—Somnolence—Methotrexate—testicular cancer	0.000933	0.000933	CcSEcCtD
Regadenoson—Hypotension—Epirubicin—testicular cancer	0.000918	0.000918	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—testicular cancer	0.000909	0.000909	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000906	0.000906	CcSEcCtD
Regadenoson—Pain—Methotrexate—testicular cancer	0.000897	0.000897	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000895	0.000895	CcSEcCtD
Regadenoson—Shock—Doxorubicin—testicular cancer	0.000894	0.000894	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—testicular cancer	0.000891	0.000891	CcSEcCtD
Regadenoson—Insomnia—Epirubicin—testicular cancer	0.000888	0.000888	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—testicular cancer	0.000887	0.000887	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—testicular cancer	0.000883	0.000883	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—testicular cancer	0.000882	0.000882	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—testicular cancer	0.000879	0.000879	CcSEcCtD
Regadenoson—Dyspnoea—Epirubicin—testicular cancer	0.000876	0.000876	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—testicular cancer	0.000873	0.000873	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—testicular cancer	0.000865	0.000865	CcSEcCtD
Regadenoson—Gastrointestinal pain—Methotrexate—testicular cancer	0.000858	0.000858	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—testicular cancer	0.000849	0.000849	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000848	0.000848	CcSEcCtD
Regadenoson—Pain—Epirubicin—testicular cancer	0.00084	0.00084	CcSEcCtD
Regadenoson—Urticaria—Methotrexate—testicular cancer	0.000834	0.000834	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—testicular cancer	0.00083	0.00083	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000828	0.000828	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—testicular cancer	0.000822	0.000822	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—testicular cancer	0.000816	0.000816	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—testicular cancer	0.00081	0.00081	CcSEcCtD
Regadenoson—Feeling abnormal—Epirubicin—testicular cancer	0.000809	0.000809	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—testicular cancer	0.000808	0.000808	CcSEcCtD
Regadenoson—Gastrointestinal pain—Epirubicin—testicular cancer	0.000803	0.000803	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000785	0.000785	CcSEcCtD
Regadenoson—Urticaria—Epirubicin—testicular cancer	0.00078	0.00078	CcSEcCtD
Regadenoson—Pain—Doxorubicin—testicular cancer	0.000777	0.000777	CcSEcCtD
Regadenoson—Abdominal pain—Epirubicin—testicular cancer	0.000776	0.000776	CcSEcCtD
Regadenoson—Hypersensitivity—Methotrexate—testicular cancer	0.000773	0.000773	CcSEcCtD
Regadenoson—Asthenia—Methotrexate—testicular cancer	0.000753	0.000753	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—testicular cancer	0.000749	0.000749	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000743	0.000743	CcSEcCtD
Regadenoson—Hypersensitivity—Epirubicin—testicular cancer	0.000724	0.000724	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—testicular cancer	0.000722	0.000722	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—testicular cancer	0.000718	0.000718	CcSEcCtD
Regadenoson—Diarrhoea—Methotrexate—testicular cancer	0.000718	0.000718	CcSEcCtD
Regadenoson—Asthenia—Epirubicin—testicular cancer	0.000705	0.000705	CcSEcCtD
Regadenoson—Dizziness—Methotrexate—testicular cancer	0.000694	0.000694	CcSEcCtD
Regadenoson—Diarrhoea—Epirubicin—testicular cancer	0.000672	0.000672	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—testicular cancer	0.00067	0.00067	CcSEcCtD
Regadenoson—Vomiting—Methotrexate—testicular cancer	0.000667	0.000667	CcSEcCtD
Regadenoson—Rash—Methotrexate—testicular cancer	0.000662	0.000662	CcSEcCtD
Regadenoson—Dermatitis—Methotrexate—testicular cancer	0.000661	0.000661	CcSEcCtD
Regadenoson—Headache—Methotrexate—testicular cancer	0.000657	0.000657	CcSEcCtD
Regadenoson—Asthenia—Doxorubicin—testicular cancer	0.000652	0.000652	CcSEcCtD
Regadenoson—Dizziness—Epirubicin—testicular cancer	0.000649	0.000649	CcSEcCtD
Regadenoson—Vomiting—Epirubicin—testicular cancer	0.000624	0.000624	CcSEcCtD
Regadenoson—Nausea—Methotrexate—testicular cancer	0.000623	0.000623	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—testicular cancer	0.000622	0.000622	CcSEcCtD
Regadenoson—Rash—Epirubicin—testicular cancer	0.000619	0.000619	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—testicular cancer	0.000619	0.000619	CcSEcCtD
Regadenoson—Headache—Epirubicin—testicular cancer	0.000615	0.000615	CcSEcCtD
Regadenoson—Dizziness—Doxorubicin—testicular cancer	0.000601	0.000601	CcSEcCtD
Regadenoson—Nausea—Epirubicin—testicular cancer	0.000583	0.000583	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—testicular cancer	0.000578	0.000578	CcSEcCtD
Regadenoson—Rash—Doxorubicin—testicular cancer	0.000573	0.000573	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—testicular cancer	0.000572	0.000572	CcSEcCtD
Regadenoson—Headache—Doxorubicin—testicular cancer	0.000569	0.000569	CcSEcCtD
Regadenoson—Nausea—Doxorubicin—testicular cancer	0.00054	0.00054	CcSEcCtD
